S695 Risankizumab Induces Early Clinical Remission and Response in Patients With Moderate-To-Severe Crohn's Disease: Results From the Phase 3 ADVANCE and MOTIVATE Studies. (October 2021) - Schreiber, Stefan; Ferrante, Marc; Panaccione, Remo; Colombel, Jean-Frederic; Hisamatsu, Tadakazu; Lim, Allen; Lindsay, James; Rubin, David T.; ,; Sandborn, William; Neimark, Ezequiel; Song, Alexandra; et al.